Skip to main content

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Berta Miró Cau, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Gloria López Comellas, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 31/12/2027

Human induced pluripotent stem cell-based chimeric mice to study astrocyte pathology and neuroprotective strategies in multiple sclerosis patients

IP: Manuel Comabella Lopez
Collaborators: Andres Miguez Gonzalez, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 286770
Reference: PI21/01611
Duration: 01/01/2022 - 30/06/2025

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: Sunny Malhotra Sareen
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

Related news

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

Related professionals

Carlos Frutos Gomez

Carlos Frutos Gomez

403
Director
Read more
Emily Betancourt Fernández

Emily Betancourt Fernández

Predoctoral researcher
Molecular Medical Imaging
Read more
Arturo Miguel Battaglia Cáceres

Arturo Miguel Battaglia Cáceres

Predoctoral researcher
Infectious Diseases
Read more
Judit Cabana Dominguez

Judit Cabana Dominguez

Main researcher
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.